A5083348527- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Histone Deacetylase Inhibitors Research
- Chronic Lymphocytic Leukemia Research
- Polyomavirus and related diseases
- Neutropenia and Cancer Infections
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Hematological disorders and diagnostics
- Lymphoma Diagnosis and Treatment
- Renal Transplantation Outcomes and Treatments
- Immune Cell Function and Interaction
- Transplantation: Methods and Outcomes
- Cancer Genomics and Diagnostics
- Cancer survivorship and care
- Engineering Applied Research
- Wireless Body Area Networks
- Neurological and metabolic disorders
- Glioma Diagnosis and Treatment
- CRISPR and Genetic Engineering
- Neurological Complications and Syndromes
- Protein Degradation and Inhibitors
Seoul St. Mary's Hospital
2020-2025
Catholic University of Korea
2020-2025
University of Pecs
2023
Abstract Venetoclax (VEN) combined with azacitidine (AZA) or decitabine (DEC) has been approved for older adults acute myeloid leukemia (AML) unfit intensive chemotherapy based on the pivotal VIALE-A trial. However, this trial only compared AZA + VEN monotherapy. Therefore, we outcomes of consecutive (65 years older) newly diagnosed AML who received DEC ( n = 230) 74) after propensity score matching to construct a one-to-one matched cohort by nearest neighbor algorithm. The median overall...
This study aimed to validate the new European Leukemia Net (ELN) 2022 criteria for genetic risk stratification in older adults with acute myeloid leukemia (AML) and determine most likely set of clusters similar cytogenetic mutation properties correlated survival outcomes three treatment groups: intensive chemotherapy (IC), hypomethylating agents (HMAs) alone, HMAs plus venetoclax (HMA/VEN). The included 279 patients (≥60 years) who received IC (n=131), HMA (n=76), HMA/VEN (n=72) between July...
Evidence that a venetoclax (VEN)-combined regimen is effective in relapsed/refractory acute myeloid leukemia (R/R AML) emerging. However, it unknown how VEN-combined low intensity treatment compares to intensive chemotherapy (IC) medically fit patients with R/R AML.We compared AML who received IC (n = 89) those VEN combination hypomethylating agents or dose cytarabine (VEN combination) 54) as their first- second-line salvage after failing anthracycline-containing chemotherapy.The median age...
Blinatumomab showed a higher complete remission (CR) rate and safe bridging to allogeneic hematopoietic cell transplantation (allo-HCT) in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R BCP-ALL).We tried analyze the outcome of blinatumomab compared real-world historical data. We expected superior conventional chemotherapy.We conducted retrospective study using data Catholic Hematology Hospital.Total 197 consecutive cases R/R BCP-ALL were treated...
Although splenectomy has long been second-line option for immune thrombocytopenia (ITP) patients, an indicator that reliably predicts the efficacy of is still being explored. We investigated treatment outcomes as a therapy relapsed/refractory ITP according to first-line intravenous immunoglobulin (IVIG) responses.Fifty-two adult patients treated with between 2009 and 2019 were included, they classified IVIG responses (no response IVIG: nonresponders; only transient shorter than 4 weeks: poor...
Recently, the combination of VEN-HMA has been shown to achieve durable responses in patients with both newly diagnosed (ND) and R/R-AML. We retrospectively evaluated post-allo-HCT outcomes 50 who received therapy. In total, 10 were ND 40 R/R and, at time HCT, median age was 53 years. ND- R/R-AML groups, percentage achieved CR/CRi or MLFS 90% 92.5%, respectively. all, after a follow-up 13.7 months, probabilities overall survival (OS), relapse-free (RFS), cumulative incidence relapse (CIR),...
To clarify the role of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in chimeric antigen receptor T-cell therapy era, we analyzed clinical characteristics and outcomes 52 patients treated with allo-HSCT relapsed/refractory diffuse large B cell lymphoma. Most enrolled had previously undergone intensive treatments, median number chemotherapy lines was 4, time from diagnosis to 27.1 months. Patients were divided into remission-achieved (n = 30) active-disease 22) groups before...
The Philadelphia-negative myeloproliferative neoplasms (MPNs) are divided in three major groups: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). 2016 WHO classification incorporates also prefibrotic PMF (pre-PMF) overt PMF. This study aimed to discriminate the clinical features, genetic alterations, outcomes patients with prefibrotic, PMF, secondary MF (SMF). included 229 diagnosed (MF). Among patients, 67 (29%), 122 (53%), 40 (18%) were confirmed as...
Background: The Short Physical Performance Battery (SPPB) and the short form of Geriatric Depression Scale (SGDS-K) predict survival outcomes in older adults with acute myeloid leukemia (AML) treated intensive chemotherapy. However, their role lower-intensity therapy remains unclear. We evaluated thier prognostic AML hypomethylating agents (HMA) or without venetoclax (VEN).Methods: This single-center, prospective cohort study was conducted at Seoul St. Mary's Hospital, Seoul, Republic Korea....
<title>Abstract</title> In this study, we analyzed clinical and genomic data from 1,585 patients diagnosed with myeloid neoplasms (MNs), including myeloproliferative (MPN, n = 715), myelodysplastic (MDS, 698), MDS/MPN (n 94), aplastic anemia (AA, 94). We identified ten distinct groups that redefine MN classification using unsupervised clustering through the Dirichlet Process (DP), correlating specific genetic mutations survival outcomes disease subtypes. Notably, DP1 DP5, characterized by...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential cure for myelodysplastic neoplasms (MDSs) and other hematologic malignancies. This study investigates post-transplantation genetic evolution telomere dynamics in cells, with focus on clonal hematopoiesis (CH). We conducted longitudinal analysis of 21 MDS patients who underwent allo-HSCT between September 2009 February 2015. Genetic profiles cells from both recipients donors were compared at equivalent pre- time...
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare, aggressive subtype of primary gastrointestinal lymphoma. Owing to the absence symptoms characteristic MEITL, diagnosis can be challenging, and low response rate conventional chemotherapy leads an abysmal prognosis. This study aimed define clinicopathologic characteristics MEITL in Korea, evaluate clinical outcomes intensive with without hematopoietic stem cell transplantation (HSCT), explore prognostic factors.
Given the limited comprehensive data on bone marrow (BM) immune environment in acute myeloid leukemia (AML), we analyzed distribution and phenotype of T cell subsets, including γδ cells, their checkpoint (IC) ligands blasts. We performed multiparametric flow cytometry with BM samples taken from 89 AML patients at time diagnosis, remission, relapse/refractory status after chemotherapy 13 healthy controls (HCs) to identify immune-related risk factors. Compared HCs, cells exhibited exhausted...